Clin Endosc.  2014 Nov;47(6):497-503. 10.5946/ce.2014.47.6.497.

Endoscopic Gastric Cancer Screening and Surveillance in High-Risk Groups

• Choi IJ

• KMID: 2134486
• DOI: http://doi.org/10.5946/ce.2014.47.6.497

Abstract

Gastric cancer remains a major cancer problem world-wide and future incidence will likely increase due to rapidly aging population demographics. Population-based screening is being undertaken in Korea and Japan, where gastric cancer incidence rates are high, and seems to be effective in reducing mortality from gastric cancer. However, such strategies are difficult to implement in countries with a low incidence or limited resources. Thus, screening strategies should be directed towards high-risk population subgroups. Gastric cancer has a relatively long mean sojourn time, and prognosis of early-stage disease is excellent. In general population, screening at 2-year interval in Korea seems to be effective for early-stage diagnosis. In subjects with atrophic gastritis or intestinal metaplasia, surveillance is recommended at 1 to 3 years intervals according to European and Japanese recommendation. Screening intervals for family members with sporadic gastric cancer has not yet been adequately evaluated, but 1-year interval is recommended for hereditary diffuse gastric cancer family-members. Gastric cancer patients treated by endoscopic resection are the highest-risk group, and 1-year interval surveillance can detect most metachronous gastric cancers at an early stage. Future gastric cancer surveillance strategies using endoscopy should be guided by risk-stratification assessment, and further refinement of optimal surveillance intervals is needed.

Keyword

Stomach neoplasms; Endoscopy; Screening; Surveillance

MeSH Terms

Aging
Asian Continental Ancestry Group
Demography
Diagnosis
Endoscopy
Gastritis, Atrophic
Humans
Incidence
Japan
Korea
Mass Screening*
Metaplasia
Mortality
Prognosis
Stomach Neoplasms*

Reference

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. Epub 2014 Sep 13. DOI: http://dx.doi.org/10.1002/ijc.29210.

2. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat. 2014; 46:109–123. PMID: 24851102.

3. Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988; 48:3554–3560. PMID: 3288329.

4. Fock KM, Talley N, Moayyedi P, et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol. 2008; 23:351–365. PMID: 18318820.

5. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection: the Maastricht IV/ Florence Consensus Report. Gut. 2012; 61:646–664. PMID: 22491499.

6. Herrero R, Parsonnet J, Greenberg ER. Prevention of gastric cancer. JAMA. 2014; 312:1197–1198. PMID: 25247512.

7. Lee KS, Oh DK, Han MA, et al. Gastric cancer screening in Korea: report on the national cancer screening program in 2008. Cancer Res Treat. 2011; 43:83–88. PMID: 21811423.

8. Hamashima C, Shibuya D, Yamazaki H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2008; 38:259–267. PMID: 18344316.

9. Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer. 2013; 132:1272–1276. PMID: 23180638.

10. Dan YY, So JB, Yeoh KG. Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol. 2006; 4:709–716. PMID: 16765306.

11. Hassan C, Quintero E, Dumonceau JM, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2013; 45:842–851. PMID: 24030244.

12. Zhou HJ, Dan YY, Naidoo N, Li SC, Yeoh KG. A cost-effectiveness analysis evaluating endoscopic surveillance for gastric cancer for populations with low to intermediate risk. PLoS One. 2013; 8:e83959. PMID: 24386314.

13. Gotoda T, Ishikawa H, Ohnishi H, et al. Randomized controlled trial comparing gastric cancer screening by gastrointestinal X-ray with serology for Helicobacter pylori and pepsinogens followed by gastrointestinal endoscopy. Gastric Cancer. Epub 2014 Aug 13. DOI: http://dx.doi.org/10.1007/s10120-014-0408-5.

14. Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008; 9:279–287. PMID: 18308253.

15. Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012; 44:74–94. PMID: 22198778.

16. Bae JM. Methodological issues for determining intervals of subsequent cancer screening. Epidemiol Health. 2014; 36:e2014010. PMID: 25078383.

17. Bae JM, Shin SY, Kim EH. Mean sojourn time of preclinical gastric cancer in Korean men: a retrospective observational study. J Prev Med Public Health. 2014; 47:201–205. PMID: 25139166.

18. Brenner H, Altenhofen L, Katalinic A, Lansdorp-Vogelaar I, Hoffmeister M. Sojourn time of preclinical colorectal cancer by sex and age: estimates from the German national screening colonoscopy database. Am J Epidemiol. 2011; 174:1140–1146. PMID: 21984657.

19. Kwak HW, Choi IJ, Cho SJ, et al. Characteristics of gastric cancer according to Helicobacter pylori infection status. J Gastroenterol Hepatol. 2014; 29:1671–1677. PMID: 24730518.

20. Park CH, Kim EH, Chung H, et al. The optimal endoscopic screening interval for detecting early gastric neoplasms. Gastrointest Endosc. 2014; 80:253–259. PMID: 24613579.

21. Nam JH, Choi IJ, Cho SJ, et al. Association of the interval between endoscopies with gastric cancer stage at diagnosis in a region of high prevalence. Cancer. 2012; 118:4953–4960. PMID: 22806878.

22. Hamashima C, Ogoshi K, Okamoto M, Shabana M, Kishimoto T, Fukao A. A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. PLoS One. 2013; 8:e79088. PMID: 24236091.

23. Yaghoobi M, Bijarchi R, Narod SA. Family history and the risk of gastric cancer. Br J Cancer. 2010; 102:237–242. PMID: 19888225.

24. Han MA, Oh MG, Choi IJ, et al. Association of family history with cancer recurrence and survival in patients with gastric cancer. J Clin Oncol. 2012; 30:701–708. PMID: 22271486.

25. Pedrazzani C, Corso G, Velho S, et al. Evidence of tumor microsatellite instability in gastric cancer with familial aggregation. Fam Cancer. 2009; 8:215–220. PMID: 19152022.

26. Corso G, Marrelli D, Pascale V, Vindigni C, Roviello F. Frequency of CDH1 germline mutations in gastric carcinoma coming from high- and low-risk areas: metanalysis and systematic review of the literature. BMC Cancer. 2012; 12:8. PMID: 22225527.

27. Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012; 61:673–684. PMID: 22315472.

28. Cancer Genome. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513:202–209. PMID: 25079317.

29. Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010; 47:436–444. PMID: 20591882.

30. Kluijt I, Sijmons RH, Hoogerbrugge N, et al. Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Fam Cancer. 2012; 11:363–369. PMID: 22388873.

31. Guilford P, Humar B, Blair V. Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer. 2010; 13:1–10. PMID: 20373070.

32. Corso G, Roncalli F, Marrelli D, Carneiro F, Roviello F. History, pathogenesis, and management of familial gastric cancer: original study of John XXIII's family. Biomed Res Int. 2013; 2013:385132. PMID: 23484115.

33. Chinese Society of Gastroenterology. Chinese Study Group on Helicobacter pylori. Liu WZ, Xie Y, et al. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. J Dig Dis. 2013; 14:211–221. PMID: 23302262.

34. Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol. 2014; 29:1371–1386. PMID: 24758240.

35. Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010; 15:1–20. PMID: 20302585.

36. Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther. 2002; 16:1249–1259. PMID: 12144574.

37. Wang J, Xu L, Shi R, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion. 2011; 83:253–260. PMID: 21282951.

38. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969; 1:87–97.

39. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis The updated Sydney System International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996; 20:1161–1181. PMID: 8827022.

40. Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008; 40:650–658. PMID: 18424244.

41. Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010; 71:1150–1158. PMID: 20381801.

42. Rugge M, de Boni M, Pennelli G, et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther. 2010; 31:1104–1111. PMID: 20180784.

43. Cho SJ, Choi IJ, Kook MC, et al. Staging of intestinal- and diffuse-type gastric cancers with the OLGA and OLGIM staging systems. Aliment Pharmacol Ther. 2013; 38:1292–1302. PMID: 24134499.

44. Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005; 54:764–768. PMID: 15888780.

45. Asaka M, Kato M, Graham DY. Strategy for eliminating gastric cancer in Japan. Helicobacter. 2010; 15:486–490. PMID: 21073603.

46. Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter. 2007; 12:333–340. PMID: 17669107.

47. Chung SJ, Park MJ, Kang SJ, et al. Effect of annual endoscopic screening on clinicopathologic characteristics and treatment modality of gastric cancer in a high-incidence region of Korea. Int J Cancer. 2012; 131:2376–2384. PMID: 22362223.

48. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011; 14:113–123. PMID: 21573742.

49. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008; 372:392–397. PMID: 18675689.

50. Nasu J, Doi T, Endo H, Nishina T, Hirasaki S, Hyodo I. Characteristics of metachronous multiple early gastric cancers after endoscopic mucosal resection. Endoscopy. 2005; 37:990–993. PMID: 16189772.

51. Jang MY, Cho JW, Oh WG, et al. Clinicopathological characteristics of synchronous and metachronous gastric neoplasms after endoscopic submucosal dissection. Korean J Intern Med. 2013; 28:687–693. PMID: 24307844.

52. Kato M, Nishida T, Yamamoto K, et al. Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD study group. Gut. 2013; 62:1425–1432. PMID: 22914298.

53. Nakajima T, Oda I, Gotoda T, et al. Metachronous gastric cancers after endoscopic resection: how effective is annual endoscopic surveillance. Gastric Cancer. 2006; 9:93–98. PMID: 16767364.

54. Kim YI, Choi IJ, Kook MC, et al. The association between Helicobacter pylori status and incidence of metachronous gastric cancer after endoscopic resection of early gastric cancer. Helicobacter. 2014; 19:194–201. PMID: 24612125.

55. Choi IJ, Lee JH, Kim YI, et al. Long-term outcome comparison of endoscopic resection and surgery in early gastric cancer meeting the absolute indication for endoscopic resection. Gastrointest Endosc. Epub 2014 Sep 30. DOI: http://dx.doi.org/10.1016/j.gie.2014.07.047.

56. Choi J, Kim SG, Yoon H, et al. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol. 2014; 12:793–800. PMID: 24100112.

57. Bae SE, Jung HY, Kang J, et al. Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. Am J Gastroenterol. 2014; 109:60–67. PMID: 24343545.

58. Maehata Y, Nakamura S, Fujisawa K, et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc. 2012; 75:39–46. PMID: 22018552.

59. Eom BW, Lee JH, Choi IJ, et al. Pretreatment risk factors for multiple gastric cancer and missed lesions. J Surg Oncol. 2012; 105:813–817. PMID: 22006627.

60. Lee HL, Eun CS, Lee OY, et al. When do we miss synchronous gastric neoplasms with endoscopy? Gastrointest Endosc. 2010; 71:1159–1165. PMID: 20381041.

61. Lee JY, Choi IJ, Cho SJ, et al. Routine follow-up biopsies after complete endoscopic resection for early gastric cancer may be unnecessary. J Gastric Cancer. 2012; 12:88–98. PMID: 22792521.

62. Kobayashi M, Narisawa R, Sato Y, Takeuchi M, Aoyagi Y. Self-limiting risk of metachronous gastric cancers after endoscopic resection. Dig Endosc. 2010; 22:169–173. PMID: 20642604.

63. Ahn HS, Kim JW, Yoo MW, et al. Clinicopathological features and surgical outcomes of patients with remnant gastric cancer after a distal gastrectomy. Ann Surg Oncol. 2008; 15:1632–1639. PMID: 18379851.

64. Park JH, Lee JH, Rhee PL, et al. Endoscopic screening for remnant gastric cancer: points to be considered. Gut Liver. 2007; 1:22–26. PMID: 20485654.

65. Lee JY, Choi IJ, Cho SJ, et al. Endoscopic submucosal dissection for metachronous tumor in the remnant stomach after distal gastrectomy. Surg Endosc. 2010; 24:1360–1366. PMID: 19997930.

66. Nonaka S, Oda I, Makazu M, et al. Endoscopic submucosal dissection for early gastric cancer in the remnant stomach after gastrectomy. Gastrointest Endosc. 2013; 78:63–72. PMID: 23566640.